Skip to main navigation
Skip to search
Skip to main content
Northwestern Scholars Home
Help & FAQ
Home
Experts
Organizations
Research Output
Grants
Core Facilities
Datasets
Search by expertise, name or affiliation
Prot #MK3475-055: A Phase II Clinical Trial of Single Agent Pembrolizumab (MK-3475) in Subjects with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Who Have Failed Platinum and Cetuximab
Agulnik, Mark
(PD/PI)
Medicine, Hematology Oncology Division
Project
:
Research project
Overview
Project Details
Status
Finished
Effective start/end date
4/17/15
→
4/17/21
Funding
Merck Sharp & Dohme Corporation
(Prot #MK3475-055)
View all
View less